Clearside Biomedical, Inc. (CLSD) 10-Year Financial Performance & Capital Metrics

CLSD • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

AboutClearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Show more

Revenue $2M -79.8%
EBITDA -$29M -15.7%
Net Income -$34M -5.7%
EPS (Diluted) -7.05 +11.3%
Gross Margin 91.05% -4.8%
EBITDA Margin -1722.12% -471.7%
Operating Margin -1735.7% -474.7%
Net Margin -2064.42% -422.8%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -2.95 -11.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 1 (bottom 1%)
✗Sales declining 5.2% over 5 years
✗Shares diluted 19.4% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-5.2%

3Y-61.68%

TTM-56.78%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM18.45%

EPS CAGR

10Y-

5Y-

3Y-

TTM23.94%

ROCE

10Y Avg-111.15%

5Y Avg-81.36%

3Y Avg-87.37%

Latest-121.51%

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	520K	345K	30K	2.17M	7.89M	29.57M	1.33M	8.23M	1.66M
Revenue Growth %	-	-	-0.34%	-0.91%	71.43%	2.63%	2.75%	-0.96%	5.2%	-0.8%
Cost of Goods Sold+	33K	0	0	0	0	0	0	204K	355K	149K
COGS % of Revenue	-	-	-	-	-	-	-	0.15%	0.04%	0.09%
Gross Profit+	-33K	520K	345K	30K	2.17M	7.89M	29.57M	1.12M	7.87M	1.51M
Gross Margin %	-	1%	1%	1%	1%	1%	1%	0.85%	0.96%	0.91%
Gross Profit Growth %	-	16.76%	-0.34%	-0.91%	71.43%	2.63%	2.75%	-0.96%	6.01%	-0.81%
Operating Expenses+	17.32M	25.72M	58.75M	82.97M	32.48M	25.83M	30.2M	31.4M	32.72M	30.4M
OpEx % of Revenue	-	49.46%	170.3%	2765.83%	14.95%	3.27%	1.02%	23.66%	3.98%	18.27%
Selling, General & Admin	6.55M	6.26M	9.7M	14.68M	16.82M	10.76M	11.66M	11.77M	11.87M	11.81M
SG&A % of Revenue	-	12.04%	28.12%	489.47%	7.74%	1.36%	0.39%	8.87%	1.44%	7.1%
Research & Development	10.76M	19.45M	49.05M	68.29M	15.66M	15.07M	18.54M	19.63M	20.85M	18.59M
R&D % of Revenue	-	37.41%	142.18%	2276.37%	7.21%	1.91%	0.63%	14.79%	2.53%	11.17%
Other Operating Expenses	0	0	-567K	127K	0	0	0	0	0	0
Operating Income+	-17.32M	-25.2M	-58.41M	-82.94M	-30.3M	-17.93M	-627K	-30.28M	-24.84M	-28.88M
Operating Margin %	-	-48.46%	-169.3%	-2764.83%	-13.95%	-2.27%	-0.02%	-22.82%	-3.02%	-17.36%
Operating Income Growth %	-0.76%	-0.46%	-1.32%	-0.42%	0.63%	0.41%	0.97%	-47.29%	0.18%	-0.16%
EBITDA+	-17.26M	-25.13M	-58.23M	-82.76M	-30.09M	-17.75M	-449K	-30.13M	-24.78M	-28.66M
EBITDA Margin %	-	-48.33%	-168.77%	-2758.53%	-13.85%	-2.25%	-0.02%	-22.71%	-3.01%	-17.22%
EBITDA Growth %	-0.76%	-0.46%	-1.32%	-0.42%	0.64%	0.41%	0.97%	-66.11%	0.18%	-0.16%
D&A (Non-Cash Add-back)	60K	65K	182K	189K	211K	180K	178K	145K	67K	226K
EBIT	-17.32M	-25.2M	-58.41M	-82.94M	-30.3M	-17.88M	376K	-29.61M	-23.13M	-24.57M
Net Interest Income+	-322K	0	0	0	0	0	0	-2.67M	-7.64M	-8.32M
Interest Income	8K	0	0	0	1.03M	335K	0	669K	1.72M	1.46M
Interest Expense	330K	0	0	0	1.03M	335K	0	3.34M	9.36M	9.78M
Other Income/Expense	-322K	-684K	-567K	127K	-466K	-275K	1M	-2.67M	-7.64M	-5.47M
Pretax Income+	-17.64M	-25.88M	-58.98M	-82.82M	-30.77M	-18.21M	376K	-32.95M	-32.48M	-34.35M
Pretax Margin %	-	-49.77%	-170.94%	-2760.6%	-14.16%	-2.31%	0.01%	-24.83%	-3.95%	-20.64%
Income Tax+	8K	-65K	-182K	127K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-17.64M	-25.88M	-58.98M	-82.82M	-30.77M	-18.21M	376K	-32.95M	-32.48M	-34.35M
Net Margin %	-	-49.77%	-170.94%	-2760.6%	-14.16%	-2.31%	0.01%	-24.83%	-3.95%	-20.64%
Net Income Growth %	-0.73%	-0.47%	-1.28%	-0.4%	0.63%	0.41%	1.02%	-88.63%	0.01%	-0.06%
Net Income (Continuing)	-17.64M	-25.88M	-58.98M	-82.82M	-30.77M	-18.21M	376K	-32.95M	-32.48M	-34.35M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-21.60	-29.55	-34.95	-40.35	-12.00	-5.85	0.09	-8.25	-7.95	-7.05
EPS Growth %	-0.73%	-0.37%	-0.18%	-0.15%	0.7%	0.51%	1.02%	-88.3%	0.04%	0.11%
EPS (Basic)	-21.60	-29.55	-34.95	-40.35	-12.00	-5.85	0.10	-8.25	-7.95	-7.05
Diluted Shares Outstanding	818.3K	874.07K	1.69M	2.05M	2.54M	3.1M	3.99M	4.01M	4.12M	4.92M
Basic Shares Outstanding	818.3K	874.07K	1.69M	2.05M	2.54M	3.1M	3.9M	4.01M	4.12M	4.92M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	20.48M	83.63M	37.64M	42.94M	25.22M	18.12M	42.14M	49.4M	30.12M	21.27M
Cash & Short-Term Investments	20.28M	83.63M	37.64M	40.88M	22.59M	17.29M	30.44M	48.42M	28.92M	20.02M
Cash Only	20.28M	34.82M	9.22M	8.04M	22.59M	17.29M	30.44M	48.42M	28.92M	20.02M
Short-Term Investments	0	48.81M	28.42M	32.84M	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	10M	0	170K	507K
Days Sales Outstanding	-	-	-	-	-	-	123.42	-	7.54	111.21
Inventory	0	0	0	0	0	0	921K	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	40K	290K	116K	17K	1.49M	109K	779K	279K	311K	13K
Total Non-Current Assets+	573K	360K	360K	1.18M	1.56M	1.2M	767K	1.9M	3.89M	3.85M
Property, Plant & Equipment	156K	94K	885K	790K	1.2M	944K	607K	1.87M	3.87M	3.82M
Fixed Asset Turnover	-	5.53x	0.39x	0.04x	1.82x	8.36x	48.72x	0.71x	2.13x	0.44x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	360K	360K	360K	0	260K	0	30K	0	0
Other Non-Current Assets	417K	-94K	-885K	26K	360K	0	160K	0	30K	30K
Total Assets+	21.05M	84.81M	40.49M	44.12M	26.78M	19.32M	42.9M	51.3M	34.02M	25.13M
Asset Turnover	-	0.01x	0.01x	0.00x	0.08x	0.41x	0.69x	0.03x	0.24x	0.07x
Asset Growth %	1.04%	3.03%	-0.52%	0.09%	-0.39%	-0.28%	1.22%	0.2%	-0.34%	-0.26%
Total Current Liabilities+	5.2M	5.41M	13.52M	10.48M	10.9M	9.94M	4.64M	5.78M	6.81M	4.79M
Accounts Payable	1.47M	2.59M	5.38M	6.87M	1.28M	2M	941K	1.05M	2.21M	1.45M
Days Payables Outstanding	16.25K	-	-	-	-	-	-	1.88K	2.27K	3.56K
Short-Term Debt	1.73M	0	3.2M	556K	1.33M	991K	0	349K	364K	0
Deferred Revenue (Current)	0	160K	140K	0	1000K	1000K	0	205K	75K	0
Other Current Liabilities	9K	23K	219K	1.86M	2.28M	1.13M	0	2.34M	2.31M	0
Current Ratio	3.94x	15.46x	2.78x	4.10x	2.31x	1.82x	9.08x	8.54x	4.42x	4.44x
Quick Ratio	3.94x	15.46x	2.78x	4.10x	2.31x	1.82x	8.88x	8.54x	4.42x	4.44x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	52.52M	7.59M	8.01M	10.02M	4.72M	616K	288K	34.91M	43.12M	59.19M
Long-Term Debt	4.24M	7.59M	4.81M	9.42M	3.82M	0	0	33.98M	41.99M	51.77M
Capital Lease Obligations	0	0	0	0	897K	616K	288K	936K	649K	328K
Deferred Tax Liabilities	47.32M	-320K	-750K	0	0	0	0	0	0	0
Other Non-Current Liabilities	258K	0	610K	605K	0	0	0	0	480K	7.09M
Total Liabilities	57.71M	13.15M	19.08M	20.5M	15.62M	10.56M	4.93M	40.7M	49.93M	63.98M
Total Debt+	5.98M	7.59M	8.01M	9.97M	6.41M	1.98M	675K	35.26M	43M	52.47M
Net Debt	-14.31M	-27.24M	-1.22M	1.93M	-16.19M	-15.31M	-29.76M	-13.16M	14.08M	32.45M
Debt / Equity	-	0.11x	0.37x	0.42x	0.57x	0.23x	0.02x	3.32x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-52.48x	-	-	-	-29.31x	-53.54x	-	-9.07x	-2.65x	-2.95x
Total Equity+	-36.66M	71.66M	21.41M	23.62M	11.16M	8.76M	37.98M	10.61M	-15.91M	-38.85M
Equity Growth %	-0.91%	2.95%	-0.7%	0.1%	-0.53%	-0.21%	3.33%	-0.72%	-2.5%	-1.44%
Book Value per Share	-44.80	81.98	12.69	11.53	4.38	2.83	9.51	2.64	-3.86	-7.90
Total Shareholders' Equity	-36.66M	71.66M	21.41M	23.62M	11.16M	8.76M	37.98M	10.61M	-15.91M	-38.85M
Common Stock	3K	25K	25K	32K	44K	52K	60K	61K	63K	77K
Retained Earnings	-39.36M	-65.25M	-124.22M	-206.89M	-237.66M	-255.87M	-255.49M	-288.44M	-320.92M	-355.27M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-103K	-13K	-8K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.9M	-22.71M	-51.08M	-79.2M	-27.07M	-13.12M	-10.73M	-13.37M	-18.14M	-24.7M
Operating CF Margin %	-	-43.67%	-148.07%	-2640%	-12.46%	-1.66%	-0.36%	-10.07%	-2.2%	-14.84%
Operating CF Growth %	-0.52%	-0.63%	-1.25%	-0.55%	0.66%	0.52%	0.18%	-0.25%	-0.36%	-0.36%
Net Income	-17.64M	-25.88M	-58.98M	-82.82M	-30.77M	-18.21M	376K	-32.95M	-32.48M	-34.35M
Depreciation & Amortization	60K	65K	182K	189K	211K	180K	178K	145K	67K	226K
Stock-Based Compensation	705K	1.31M	3.36M	4.79M	4.61M	3.6M	5.05M	4.88M	4.2M	4.51M
Deferred Taxes	75K	65K	181K	-748K	-52K	0	0	0	0	0
Other Non-Cash Items	156K	439K	211K	266K	230K	188K	-998K	3.32M	9.36M	6.59M
Working Capital Changes	2.74M	1.29M	3.95M	-874K	-1.3M	1.12M	-15.34M	11.24M	720K	-1.68M
Change in Receivables	0	0	0	0	0	1.89M	-10.87M	10.42M	-220K	-51K
Change in Inventory	0	0	0	0	0	0	-681K	0	0	0
Change in Payables	0	1.42M	4.71M	-314K	-5.58M	0	681K	694K	614K	-1.43M
Cash from Investing+	-28K	-49.14M	20.12M	-3.76M	32.92M	-55K	0	-246K	-1.78M	-638K
Capital Expenditures	-32K	-3K	-306K	-88K	-25K	-55K	0	-246K	-1.78M	-977K
CapEx % of Revenue	-	0.01%	0.89%	2.93%	0.01%	0.01%	-	0.19%	0.22%	0.59%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	4K	-360K	20.12M	660K	0	0	0	0	0	0
Cash from Financing+	25.94M	86.39M	5.36M	81.78M	8.7M	7.87M	23.78M	31.33M	414K	16.44M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	14K	31K	305K	515K	52K	258K	499K	0	-1.25M	47K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-13.93M	-22.71M	-51.39M	-79.29M	-27.09M	-13.18M	-10.73M	-13.61M	-19.91M	-25.68M
FCF Margin %	-	-43.68%	-148.95%	-2642.93%	-12.47%	-1.67%	-0.36%	-10.26%	-2.42%	-15.43%
FCF Growth %	-0.5%	-0.63%	-1.26%	-0.54%	0.66%	0.51%	0.19%	-0.27%	-0.46%	-0.29%
FCF per Share	-17.03	-25.98	-30.45	-38.70	-10.65	-4.25	-2.69	-3.39	-4.83	-5.22
FCF Conversion (FCF/Net Income)	0.79x	0.88x	0.87x	0.96x	0.88x	0.72x	-28.55x	0.41x	0.56x	0.72x
Interest Paid	0	0	0	0	0	524K	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-147.9%	-126.73%	-367.79%	-176.96%	-182.83%	1.61%	-135.63%	-	-
Return on Invested Capital (ROIC)	-	-42.54%	-135.58%	-271.94%	-221.49%	-	-56.32%	-801.69%	-	-
Gross Margin	-	100%	100%	100%	100%	100%	100%	84.63%	95.68%	91.05%
Net Margin	-	-4977.31%	-17094.2%	-276060%	-1416.01%	-230.68%	1.27%	-2482.82%	-394.91%	-2064.42%
Debt / Equity	-	0.11x	0.37x	0.42x	0.57x	0.23x	0.02x	3.32x	-	-
Interest Coverage	-52.48x	-	-	-	-29.31x	-53.54x	-	-9.07x	-2.65x	-2.95x
FCF Conversion	0.79x	0.88x	0.87x	0.96x	0.88x	0.72x	-28.55x	0.41x	0.56x	0.72x
Revenue Growth	-	-	-33.65%	-91.3%	7143.33%	263.28%	274.65%	-95.51%	519.89%	-79.77%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
License	-	-	-	-	1.3M	8.2M	1.7M
License Growth	-	-	-	-	-	530.77%	-79.27%
Product and Service, Other	-	-	-	-	-	-	700K
Product and Service, Other Growth	-	-	-	-	-	-	-
Other Agreement	-	-	200K	13K	-	-	-
Other Agreement Growth	-	-	-	-93.50%	-	-	-
License And Service	30K	105K	-	-	-	-	-
License And Service Growth	-	250.00%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Clearside Biomedical, Inc. (CLSD) reported $3.3M in revenue for fiscal year 2024.

Clearside Biomedical, Inc. (CLSD) saw revenue decline by 79.8% over the past year.

Clearside Biomedical, Inc. (CLSD) reported a net loss of $26.0M for fiscal year 2024.

Dividend & Returns

Clearside Biomedical, Inc. (CLSD) had negative free cash flow of $21.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Clearside Biomedical, Inc. (CLSD) 10-Year Financial Performance & Capital Metrics

CLSD • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

Revenue $2M -79.8%
EBITDA -$29M -15.7%
Net Income -$34M -5.7%
EPS (Diluted) -7.05 +11.3%
Gross Margin 91.05% -4.8%
EBITDA Margin -1722.12% -471.7%
Operating Margin -1735.7% -474.7%
Net Margin -2064.42% -422.8%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -2.95 -11.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 1 (bottom 1%)
✗Sales declining 5.2% over 5 years
✗Shares diluted 19.4% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-5.2%

3Y-61.68%

TTM-56.78%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM18.45%

EPS CAGR

10Y-

5Y-

3Y-

TTM23.94%

ROCE

10Y Avg-111.15%

5Y Avg-81.36%

3Y Avg-87.37%

Latest-121.51%

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	520K	345K	30K	2.17M	7.89M	29.57M	1.33M	8.23M	1.66M
Revenue Growth %	-	-	-0.34%	-0.91%	71.43%	2.63%	2.75%	-0.96%	5.2%	-0.8%
Cost of Goods Sold+	33K	0	0	0	0	0	0	204K	355K	149K
COGS % of Revenue	-	-	-	-	-	-	-	0.15%	0.04%	0.09%
Gross Profit+	-33K	520K	345K	30K	2.17M	7.89M	29.57M	1.12M	7.87M	1.51M
Gross Margin %	-	1%	1%	1%	1%	1%	1%	0.85%	0.96%	0.91%
Gross Profit Growth %	-	16.76%	-0.34%	-0.91%	71.43%	2.63%	2.75%	-0.96%	6.01%	-0.81%
Operating Expenses+	17.32M	25.72M	58.75M	82.97M	32.48M	25.83M	30.2M	31.4M	32.72M	30.4M
OpEx % of Revenue	-	49.46%	170.3%	2765.83%	14.95%	3.27%	1.02%	23.66%	3.98%	18.27%
Selling, General & Admin	6.55M	6.26M	9.7M	14.68M	16.82M	10.76M	11.66M	11.77M	11.87M	11.81M
SG&A % of Revenue	-	12.04%	28.12%	489.47%	7.74%	1.36%	0.39%	8.87%	1.44%	7.1%
Research & Development	10.76M	19.45M	49.05M	68.29M	15.66M	15.07M	18.54M	19.63M	20.85M	18.59M
R&D % of Revenue	-	37.41%	142.18%	2276.37%	7.21%	1.91%	0.63%	14.79%	2.53%	11.17%
Other Operating Expenses	0	0	-567K	127K	0	0	0	0	0	0
Operating Income+	-17.32M	-25.2M	-58.41M	-82.94M	-30.3M	-17.93M	-627K	-30.28M	-24.84M	-28.88M
Operating Margin %	-	-48.46%	-169.3%	-2764.83%	-13.95%	-2.27%	-0.02%	-22.82%	-3.02%	-17.36%
Operating Income Growth %	-0.76%	-0.46%	-1.32%	-0.42%	0.63%	0.41%	0.97%	-47.29%	0.18%	-0.16%
EBITDA+	-17.26M	-25.13M	-58.23M	-82.76M	-30.09M	-17.75M	-449K	-30.13M	-24.78M	-28.66M
EBITDA Margin %	-	-48.33%	-168.77%	-2758.53%	-13.85%	-2.25%	-0.02%	-22.71%	-3.01%	-17.22%
EBITDA Growth %	-0.76%	-0.46%	-1.32%	-0.42%	0.64%	0.41%	0.97%	-66.11%	0.18%	-0.16%
D&A (Non-Cash Add-back)	60K	65K	182K	189K	211K	180K	178K	145K	67K	226K
EBIT	-17.32M	-25.2M	-58.41M	-82.94M	-30.3M	-17.88M	376K	-29.61M	-23.13M	-24.57M
Net Interest Income+	-322K	0	0	0	0	0	0	-2.67M	-7.64M	-8.32M
Interest Income	8K	0	0	0	1.03M	335K	0	669K	1.72M	1.46M
Interest Expense	330K	0	0	0	1.03M	335K	0	3.34M	9.36M	9.78M
Other Income/Expense	-322K	-684K	-567K	127K	-466K	-275K	1M	-2.67M	-7.64M	-5.47M
Pretax Income+	-17.64M	-25.88M	-58.98M	-82.82M	-30.77M	-18.21M	376K	-32.95M	-32.48M	-34.35M
Pretax Margin %	-	-49.77%	-170.94%	-2760.6%	-14.16%	-2.31%	0.01%	-24.83%	-3.95%	-20.64%
Income Tax+	8K	-65K	-182K	127K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-17.64M	-25.88M	-58.98M	-82.82M	-30.77M	-18.21M	376K	-32.95M	-32.48M	-34.35M
Net Margin %	-	-49.77%	-170.94%	-2760.6%	-14.16%	-2.31%	0.01%	-24.83%	-3.95%	-20.64%
Net Income Growth %	-0.73%	-0.47%	-1.28%	-0.4%	0.63%	0.41%	1.02%	-88.63%	0.01%	-0.06%
Net Income (Continuing)	-17.64M	-25.88M	-58.98M	-82.82M	-30.77M	-18.21M	376K	-32.95M	-32.48M	-34.35M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-21.60	-29.55	-34.95	-40.35	-12.00	-5.85	0.09	-8.25	-7.95	-7.05
EPS Growth %	-0.73%	-0.37%	-0.18%	-0.15%	0.7%	0.51%	1.02%	-88.3%	0.04%	0.11%
EPS (Basic)	-21.60	-29.55	-34.95	-40.35	-12.00	-5.85	0.10	-8.25	-7.95	-7.05
Diluted Shares Outstanding	818.3K	874.07K	1.69M	2.05M	2.54M	3.1M	3.99M	4.01M	4.12M	4.92M
Basic Shares Outstanding	818.3K	874.07K	1.69M	2.05M	2.54M	3.1M	3.9M	4.01M	4.12M	4.92M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	20.48M	83.63M	37.64M	42.94M	25.22M	18.12M	42.14M	49.4M	30.12M	21.27M
Cash & Short-Term Investments	20.28M	83.63M	37.64M	40.88M	22.59M	17.29M	30.44M	48.42M	28.92M	20.02M
Cash Only	20.28M	34.82M	9.22M	8.04M	22.59M	17.29M	30.44M	48.42M	28.92M	20.02M
Short-Term Investments	0	48.81M	28.42M	32.84M	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	10M	0	170K	507K
Days Sales Outstanding	-	-	-	-	-	-	123.42	-	7.54	111.21
Inventory	0	0	0	0	0	0	921K	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	40K	290K	116K	17K	1.49M	109K	779K	279K	311K	13K
Total Non-Current Assets+	573K	360K	360K	1.18M	1.56M	1.2M	767K	1.9M	3.89M	3.85M
Property, Plant & Equipment	156K	94K	885K	790K	1.2M	944K	607K	1.87M	3.87M	3.82M
Fixed Asset Turnover	-	5.53x	0.39x	0.04x	1.82x	8.36x	48.72x	0.71x	2.13x	0.44x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	360K	360K	360K	0	260K	0	30K	0	0
Other Non-Current Assets	417K	-94K	-885K	26K	360K	0	160K	0	30K	30K
Total Assets+	21.05M	84.81M	40.49M	44.12M	26.78M	19.32M	42.9M	51.3M	34.02M	25.13M
Asset Turnover	-	0.01x	0.01x	0.00x	0.08x	0.41x	0.69x	0.03x	0.24x	0.07x
Asset Growth %	1.04%	3.03%	-0.52%	0.09%	-0.39%	-0.28%	1.22%	0.2%	-0.34%	-0.26%
Total Current Liabilities+	5.2M	5.41M	13.52M	10.48M	10.9M	9.94M	4.64M	5.78M	6.81M	4.79M
Accounts Payable	1.47M	2.59M	5.38M	6.87M	1.28M	2M	941K	1.05M	2.21M	1.45M
Days Payables Outstanding	16.25K	-	-	-	-	-	-	1.88K	2.27K	3.56K
Short-Term Debt	1.73M	0	3.2M	556K	1.33M	991K	0	349K	364K	0
Deferred Revenue (Current)	0	160K	140K	0	1000K	1000K	0	205K	75K	0
Other Current Liabilities	9K	23K	219K	1.86M	2.28M	1.13M	0	2.34M	2.31M	0
Current Ratio	3.94x	15.46x	2.78x	4.10x	2.31x	1.82x	9.08x	8.54x	4.42x	4.44x
Quick Ratio	3.94x	15.46x	2.78x	4.10x	2.31x	1.82x	8.88x	8.54x	4.42x	4.44x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	52.52M	7.59M	8.01M	10.02M	4.72M	616K	288K	34.91M	43.12M	59.19M
Long-Term Debt	4.24M	7.59M	4.81M	9.42M	3.82M	0	0	33.98M	41.99M	51.77M
Capital Lease Obligations	0	0	0	0	897K	616K	288K	936K	649K	328K
Deferred Tax Liabilities	47.32M	-320K	-750K	0	0	0	0	0	0	0
Other Non-Current Liabilities	258K	0	610K	605K	0	0	0	0	480K	7.09M
Total Liabilities	57.71M	13.15M	19.08M	20.5M	15.62M	10.56M	4.93M	40.7M	49.93M	63.98M
Total Debt+	5.98M	7.59M	8.01M	9.97M	6.41M	1.98M	675K	35.26M	43M	52.47M
Net Debt	-14.31M	-27.24M	-1.22M	1.93M	-16.19M	-15.31M	-29.76M	-13.16M	14.08M	32.45M
Debt / Equity	-	0.11x	0.37x	0.42x	0.57x	0.23x	0.02x	3.32x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-52.48x	-	-	-	-29.31x	-53.54x	-	-9.07x	-2.65x	-2.95x
Total Equity+	-36.66M	71.66M	21.41M	23.62M	11.16M	8.76M	37.98M	10.61M	-15.91M	-38.85M
Equity Growth %	-0.91%	2.95%	-0.7%	0.1%	-0.53%	-0.21%	3.33%	-0.72%	-2.5%	-1.44%
Book Value per Share	-44.80	81.98	12.69	11.53	4.38	2.83	9.51	2.64	-3.86	-7.90
Total Shareholders' Equity	-36.66M	71.66M	21.41M	23.62M	11.16M	8.76M	37.98M	10.61M	-15.91M	-38.85M
Common Stock	3K	25K	25K	32K	44K	52K	60K	61K	63K	77K
Retained Earnings	-39.36M	-65.25M	-124.22M	-206.89M	-237.66M	-255.87M	-255.49M	-288.44M	-320.92M	-355.27M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-103K	-13K	-8K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.9M	-22.71M	-51.08M	-79.2M	-27.07M	-13.12M	-10.73M	-13.37M	-18.14M	-24.7M
Operating CF Margin %	-	-43.67%	-148.07%	-2640%	-12.46%	-1.66%	-0.36%	-10.07%	-2.2%	-14.84%
Operating CF Growth %	-0.52%	-0.63%	-1.25%	-0.55%	0.66%	0.52%	0.18%	-0.25%	-0.36%	-0.36%
Net Income	-17.64M	-25.88M	-58.98M	-82.82M	-30.77M	-18.21M	376K	-32.95M	-32.48M	-34.35M
Depreciation & Amortization	60K	65K	182K	189K	211K	180K	178K	145K	67K	226K
Stock-Based Compensation	705K	1.31M	3.36M	4.79M	4.61M	3.6M	5.05M	4.88M	4.2M	4.51M
Deferred Taxes	75K	65K	181K	-748K	-52K	0	0	0	0	0
Other Non-Cash Items	156K	439K	211K	266K	230K	188K	-998K	3.32M	9.36M	6.59M
Working Capital Changes	2.74M	1.29M	3.95M	-874K	-1.3M	1.12M	-15.34M	11.24M	720K	-1.68M
Change in Receivables	0	0	0	0	0	1.89M	-10.87M	10.42M	-220K	-51K
Change in Inventory	0	0	0	0	0	0	-681K	0	0	0
Change in Payables	0	1.42M	4.71M	-314K	-5.58M	0	681K	694K	614K	-1.43M
Cash from Investing+	-28K	-49.14M	20.12M	-3.76M	32.92M	-55K	0	-246K	-1.78M	-638K
Capital Expenditures	-32K	-3K	-306K	-88K	-25K	-55K	0	-246K	-1.78M	-977K
CapEx % of Revenue	-	0.01%	0.89%	2.93%	0.01%	0.01%	-	0.19%	0.22%	0.59%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	4K	-360K	20.12M	660K	0	0	0	0	0	0
Cash from Financing+	25.94M	86.39M	5.36M	81.78M	8.7M	7.87M	23.78M	31.33M	414K	16.44M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	14K	31K	305K	515K	52K	258K	499K	0	-1.25M	47K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-13.93M	-22.71M	-51.39M	-79.29M	-27.09M	-13.18M	-10.73M	-13.61M	-19.91M	-25.68M
FCF Margin %	-	-43.68%	-148.95%	-2642.93%	-12.47%	-1.67%	-0.36%	-10.26%	-2.42%	-15.43%
FCF Growth %	-0.5%	-0.63%	-1.26%	-0.54%	0.66%	0.51%	0.19%	-0.27%	-0.46%	-0.29%
FCF per Share	-17.03	-25.98	-30.45	-38.70	-10.65	-4.25	-2.69	-3.39	-4.83	-5.22
FCF Conversion (FCF/Net Income)	0.79x	0.88x	0.87x	0.96x	0.88x	0.72x	-28.55x	0.41x	0.56x	0.72x
Interest Paid	0	0	0	0	0	524K	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-147.9%	-126.73%	-367.79%	-176.96%	-182.83%	1.61%	-135.63%	-	-
Return on Invested Capital (ROIC)	-	-42.54%	-135.58%	-271.94%	-221.49%	-	-56.32%	-801.69%	-	-
Gross Margin	-	100%	100%	100%	100%	100%	100%	84.63%	95.68%	91.05%
Net Margin	-	-4977.31%	-17094.2%	-276060%	-1416.01%	-230.68%	1.27%	-2482.82%	-394.91%	-2064.42%
Debt / Equity	-	0.11x	0.37x	0.42x	0.57x	0.23x	0.02x	3.32x	-	-
Interest Coverage	-52.48x	-	-	-	-29.31x	-53.54x	-	-9.07x	-2.65x	-2.95x
FCF Conversion	0.79x	0.88x	0.87x	0.96x	0.88x	0.72x	-28.55x	0.41x	0.56x	0.72x
Revenue Growth	-	-	-33.65%	-91.3%	7143.33%	263.28%	274.65%	-95.51%	519.89%	-79.77%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
License	-	-	-	-	1.3M	8.2M	1.7M
License Growth	-	-	-	-	-	530.77%	-79.27%
Product and Service, Other	-	-	-	-	-	-	700K
Product and Service, Other Growth	-	-	-	-	-	-	-
Other Agreement	-	-	200K	13K	-	-	-
Other Agreement Growth	-	-	-	-93.50%	-	-	-
License And Service	30K	105K	-	-	-	-	-
License And Service Growth	-	250.00%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Clearside Biomedical, Inc. (CLSD) reported $3.3M in revenue for fiscal year 2024.

Clearside Biomedical, Inc. (CLSD) saw revenue decline by 79.8% over the past year.

Clearside Biomedical, Inc. (CLSD) reported a net loss of $26.0M for fiscal year 2024.

Dividend & Returns

Clearside Biomedical, Inc. (CLSD) had negative free cash flow of $21.7M in fiscal year 2024, likely due to heavy capital investments.